Overview

The King’s College London Gene Therapy Vector Facility (GTVF) provides cutting-edge solutions in manufacturing, process development, and quality control to support your cell and gene therapy programs.

Manufacturing – Scalable GMP-grade manufacturing of LV, RV, and AAV as either drug substance or drug product.
Process Development – Custom solutions from engineering batch manufacturing to plasmid optimization, bespoke assay development, and tailored process innovations.
Quality Control – Comprehensive in-house and outsourced QC testing, along with shelf life, and in-use stability studies.
QP Release available

We understand the financial challenges of early-stage clinical trials, which is why our competitive pricing enables both grant funded and commercial groups to bring their therapies to the clinic without being hindered by commercial price tags.

GMP facilities, available for the manufacture of:

illustration of vector cells with dna double helix

Lentiviral
Vectors (LV)

Find out more

illustration of vector cells with dna double helix

Retroviral
Vectors (RV)

Find out more

illustration of vector cells with dna double helix

Adeno-Associated
Viral Vectors (AAV)

Find out more

Infrastructure

GMP Cleanrooms

The GTVF holds four state-of-the-art, MHRA accredited GMP facilities over multiple sites, which are available for lentiviral vector (LV), Retroviral Vector (RV) and Adeno-associated Viral Vector (AAV) production.

Our significant GMP lab space enables concurrent manufacture of GMP viral vector. Combining extensive cleanroom space with a large team of ~60, the GTVF is able to service a high volume of client projects, and work to their timelines. Over the next 12-24 months, further brand new, fully-equipped independent cleanrooms are to be opened which will further enhance available capacity for client projects, and bring down lead times.

Cleanrooms at Gene Therapy Vector Facility